Nonhormonal, nonsteroidal male contraceptive agent

Archie Digital Collections

Show simple item record

dc.contributor.author White, Andrew
dc.date.accessioned 2006-06-29T20:45:22Z
dc.date.available 2006-06-29T20:45:22Z
dc.date.issued 2006-06-29T20:45:22Z
dc.identifier.uri http://hdl.handle.net/2271/131
dc.description Public Health & Outcome II Room G025 Dykes 11:00 AM Abstract 190 en
dc.description.abstract Each year there are tens of millions of unplanned pregnancies and subsequent abortions worldwide. The WHO, NIH and IOM have identified the need for the development of an effective reversible male contraceptive agent. With that goal in mind, we set out first to develop a new simpler and more cost effective method of evaluating potential male contraceptive agents and secondly to test the efficacy of one such potential male contraceptive agent. N-butyldeoxynojirimycin (NB-DNJ) has been proposed in published research to be an orally available reversible male contraceptive agent as a disruptor of sperm acrosome development. We tested NB-DNJ for efficacy in rats by oral lavage once daily over a three week period at 15 mg/kg/day. Rats were weighed daily and testis weight was determined at the time of sacrifice. Testis sections and semen smears were processed for acrosomal and nuclear staining using FITC-peanut agglutinin and DAPI fluorescence. Our results demonstrated a partial inhibition of acrosome development. Some animals showed no inhibition of acrosome development, while others had mixed populations of 1) tubules with only early round spermatid acrosomal features, 2) normal elongated nuclei but lacking acrosomes, and 3) normal elongated nuclei and acrosomes. Prior research had shown a complete inhibition of sperm maturation while our research showed minimal signs of inhibition at a similar dose level. Although both studies used the same daily dose, the major difference was that NB-DNJ was mixed in the rat’s food instead of the single daily oral dose that we employed. Our research brings up important questions regarding acceptable administration methods for screening of potential male contraceptive agents. en
dc.description.sponsorship Tash, Joseph Molecular and Integrative Physiology en
dc.format.extent 11132416 bytes
dc.format.mimetype application/vnd.ms-powerpoint
dc.language.iso en_US en
dc.subject contraceptive en
dc.title Nonhormonal, nonsteroidal male contraceptive agent en
dc.type Presentation en

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Archie


Advanced Search

Browse

My Account

Statistics